Orphan drug status applies to therapies that will treat fewer than 200,000 patients in the United States.
Mustang Bio announced Wednesday that FDA has granted Orphan Drug Designation to MB-102, an investigational chimeric antigen receptor (CAR) T-cell therapy that is being studied for the treatment of acute myeloid leukemia (AML). The FDA had previously granted Orphan Drug Designation to MB-102 for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN).
MB-102, also known as CD123 CAR T, is engineered using a patient’s T cells to recognize and eliminate CD123-expressing tumors. CD123, a molecule that helps transmit interleukin-3, is a key biomarker and treatment target for patients with myelodysplastic syndromes and several types of hematologic malignancies, including AML and BPDCN. These patients express CD123 in bone marrow cells (CD123 is also expressed in of B-cell acute lymphoblastic leukemia, hairy cell leukemia, BPDCN, chronic myeloid leukemia and Hodgkin’s lymphoma.)
According to a statement from Mustang, the investigational treatment has demonstrated complete responses in patients with AML in low doses during first-in-human clinical trial at City of Hope, with these results reported at the 2017 meeting of the American Society of Hematology and the American Association of Cancer Research Special Conference on Tumor Immunology and Immunotherapy in November 2018. The statement said dose escalation studies are ongoing at City of Hope.
“We are pleased that MB-102 has received Orphan Drug Designation in two indications, AML and BPDCN,” Manuel Litchman, MD, president and chief executive officer of Mustang, said in a statement. “AML most commonly occurs in senior adults, many of whom have to forgo chemotherapy due to other health conditions. MB-102 has the potential to be an important new treatment for these and other patients, and to potentially address multiple areas of high unmet medical need. We expect to initiate a multicenter phase 1/2 clinical trial in patients with AML, BPDCN and high-risk myelodysplastic syndrome in the coming months.”
MB-102 is currently being studied in a City of Hope, first-in-human Phase 1 dose-escalation clinical trial evaluating the safety and anti-tumor activity of escalating doses of MB-102 in patients with relapsed or refractory AML (cohort 1) and BPDCN (cohort 2). Patients receive a single dose of MB-102 with an option for a second infusion if they continue to meet safety and eligibility criteria and still have CD123+ disease. MB-102 has demonstrated complete responses at low doses in AML and BPDCN without dose-limiting toxicities. City of Hope developed CD123 CAR T.
FDA’s Orphan Drug Designation is applied to drugs that affect fewer than 200,000 people in the United States. The designation offers tax credits toward the cost of clinical trials and prescription drug use fee waivers. If approved under this status, the drug gains 7 years of market exclusivity.
Persistence Pays Off With Zanubrutinib: A Challenging CLL Case With a Prior BTK Inhibitor Failure
May 10th 2024The case of a 77-year-old woman with a long chronic lymphocytic leukemia (CLL) history illustrates the novel use of zanubrutinib as a potential option for some patients who have failed first-generation Bruton tyrosine kinase (BTK) inhibitors and venetoclax.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Margin Status Likely Not a Factor in STS Recurrence
May 10th 2024The optimal negative margin required following surgical resection and perioperative radiotherapy for extremity soft tissue sarcoma (STS) remains up for debate, with investigators of a new study using Union for International Cancer Control classification to define resection margin.
Read More
A Focus on Women: AUA Best Posters Highlight Female Athletes, Prenatal Care, and Women in Urology
May 9th 2024Three posters from the American Urological Association (AUA) 2024 Annual Meeting focused on urinary incontinence in female athletes, prenatal care for fetuses with spina bifida in California, and the experiences of women residents at the Brady Urological Institute.
Read More